Is Olaratumab registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 0 valid registrations of Olaratumab.

Is Olaratumab approved by the US FDA?

Drugs@FDA lists 1 application product line for Olaratumab, including LARTRUVO (Discontinued).

Is Olaratumab authorised in the European Union?

EMA lists 0 centrally authorised medicines containing Olaratumab.

Active substance

Olaratumab

SFDA 1
US FDA 1
EMA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
LARTRUVO 10 mg/ml Concentrate For Solution For Infusion	10 mg/ml	Injection · Intravenous use	1 Vial	SAR 6087.85	Biological · Prescription	Eli Lilly and Company	Withdrawn by MAH · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
LARTRUVO	500MG/50ML	injectable · injection	ELI LILLY AND CO	Discontinued	19 Oct 2016

EMA European Union — centrally authorised medicines

Lartruvo Eli Lilly Nederland B.V. · Revoked · authorised 9 Nov 2016 · ATC L01XC27

Therapeutic indication (EMA)

Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.